The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins
- 14 December 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 139 (1), 101-111
- https://doi.org/10.1111/j.1365-2249.2005.02665.x
Abstract
The bisphosphonates are a novel class of drug that have been registered for various clinical applications worldwide. Bisphosphonates, and in particular the aminobisphosphonates (nBPs), are known to have a number of side-effects including a rise in body temperature and accompanying flu-like symptoms that resemble a typical acute phase response. The mechanism for this response has been partially elucidated and appears to be associated with the release of tumour necrosis factor (TNF)alpha and interleukin (IL)6, although the effector cells that release these cytokines and the mechanism of action remain enigmatic. Here, we show that the nBP-induced acute phase response differs from the typical acute phase response in that CD14+ cells such as monocytes and macrophages are not the primary cytokine producing cells. We show that by inhibiting the mevalonate pathway, nBPs induce rapid and copious production of TNFalpha and IL6 by peripheral blood gammadelta T cells. Prior treatment with statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, blocks nBP-induced production of these proinflammatory cytokines by gammadelta T cells and may offer a means of avoiding the associated acute phase response. In addition, our findings provide a further mechanism for the anti-inflammatory effects attributed to inhibitors of HMG CoA reductase.Keywords
This publication has 85 references indexed in Scilit:
- Statins and their potential targets in multiple sclerosis therapyEmerging Therapeutic Targets, 2003
- High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL StudyCell Metabolism, 2003
- Anti-inflammatory and immunomodulatory effects of statinsKidney International, 2003
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- Dose‐Proportional Pharmacokinetics of Risedronate on Single‐Dose Oral Administration to Healthy VolunteersThe Journal of Clinical Pharmacology, 2000
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Nitrogen-Containing Bisphosphonates Inhibit Isopentenyl Pyrophosphate Isomerase/Farnesyl Pyrophosphate Synthase Activity with Relative Potencies Corresponding to Their Antiresorptive Potenciesin Vitroandin VivoBiochemical and Biophysical Research Communications, 1999
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999
- Regulation of IgE Responses to Inhaled Antigen in Mice by Antigen-Specific γδ T CellsScience, 1994
- PamidronateDrugs, 1991